Christopher Anzalone, Ph.D., President and CEO at Arrowhead, said: “Arrowhead has made significant progress this year with our pipeline. We now have 14 investigational RNAi-based medicines in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback